Intellia Therapeutics has presented landmark clinical data at the 2026 ACAAI Annual Scientific Meeting demonstrating that a single 50 mg dose of its investigational in vivo CRISPR gene-editing therapy, lonvoguran ziclumeran (lonvo-z), reduces monthly inflammatory attacks by 81% in patients with hereditary angioedema (HAE). Remarkably, 100% of treated patients across Phase 1/2 and Phase 3 HAELO trials remained completely free of long-term prophylactic medications, with 96% describing the therapy as optimal for transforming a life-threatening genetic condition into a manageable state without chronic injections.
About the Author
